ClinicaliQ Trial Snapshot
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Active Not Recruiting • Phase III • Oncology • NCT04538664.
- Adding amivantamab to standard chemotherapy improves progression-free survival in advanced lung cancer with EGFR exon 20 mutations.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations. Conditions: Carcinoma, Non-Small-Cell Lung Interventions: Amivantamab, Pemetrexed, Carboplatin, Pemetrexed Lead Sponsor: Janssen Research & Development, LLC Planned Enrollment: 308 participants